Helen C Fox1, Mehmet Sofuoglu, Peter T Morgan, Keri L Tuit, Rajita Sinha. 1. The Connecticut Mental Health Center, Yale University School of Medicine, Department of Psychiatry, 34 Park Street, New Haven, CT 06519, USA. Electronic address: helen.fox@yale.edu.
Abstract
AIMS: Exogenous progesterone has been shown to attenuate the rewarding effects of cocaine. However, its effects on provoked drug craving, stress arousal and cognitive performance has not been systematically investigated in cocaine dependent men and women. Thus, we conducted a double-blind placebo-controlled study assessing the efficacy of progesterone in reducing provoked drug craving, stress system arousal and improving cognitive performance in cocaine dependent men and women. METHODS:Forty-two early abstinent treatment-seeking cocaine dependent individuals were randomly assigned to either daily doses of placebo (12M/9F) or micronized progesterone (12M/9F) (400 mg/day), for 7 days. Under experimental conditions, all subjects were exposed to three 5-min personalized guided imagery conditions (stress, cocaine cue, relaxing), one per day, consecutively in a random, counterbalanced order. Subjective craving, mood, hypothalamic-pituitary-adrenal (HPA) and cardiovascular output, and a cognitive measure of inhibitory control (Stroop Color Word Task) were assessed pre- and post imagery. RESULTS:Progesterone relative to placebo significantly decreased cue-induced craving and cortisol responses and increased cue-induced ACTH. In addition, women but not men receiving progesterone reported lower ratings of negative emotion and higher ratings of relaxed mood following stress exposure. Improved Stroop performance was observed in all participants receiving progesterone, across all conditions. CONCLUSIONS:Progesterone was selectively effective in reducing cocaine cue-induced but not stress-related cocaine craving as well as specific measures of the provoked arousal state. Findings suggest that progesterone's effects on drug craving and arousal are moderated by both the type of environmental cue exposure and gender.
RCT Entities:
AIMS: Exogenous progesterone has been shown to attenuate the rewarding effects of cocaine. However, its effects on provoked drug craving, stress arousal and cognitive performance has not been systematically investigated in cocaine dependent men and women. Thus, we conducted a double-blind placebo-controlled study assessing the efficacy of progesterone in reducing provoked drug craving, stress system arousal and improving cognitive performance in cocaine dependent men and women. METHODS: Forty-two early abstinent treatment-seeking cocaine dependent individuals were randomly assigned to either daily doses of placebo (12M/9F) or micronized progesterone (12M/9F) (400 mg/day), for 7 days. Under experimental conditions, all subjects were exposed to three 5-min personalized guided imagery conditions (stress, cocaine cue, relaxing), one per day, consecutively in a random, counterbalanced order. Subjective craving, mood, hypothalamic-pituitary-adrenal (HPA) and cardiovascular output, and a cognitive measure of inhibitory control (Stroop Color Word Task) were assessed pre- and post imagery. RESULTS:Progesterone relative to placebo significantly decreased cue-induced craving and cortisol responses and increased cue-induced ACTH. In addition, women but not men receiving progesterone reported lower ratings of negative emotion and higher ratings of relaxed mood following stress exposure. Improved Stroop performance was observed in all participants receiving progesterone, across all conditions. CONCLUSIONS:Progesterone was selectively effective in reducing cocaine cue-induced but not stress-related cocaine craving as well as specific measures of the provoked arousal state. Findings suggest that progesterone's effects on drug craving and arousal are moderated by both the type of environmental cue exposure and gender.
Authors: G A van Wingen; F van Broekhoven; R J Verkes; K M Petersson; T Bäckström; J K Buitelaar; G Fernández Journal: Mol Psychiatry Date: 2007-06-19 Impact factor: 15.992
Authors: Helen C Fox; Kwangik A Hong; Prashni Paliwal; Peter T Morgan; Rajita Sinha Journal: Psychopharmacology (Berl) Date: 2007-09-21 Impact factor: 4.530
Authors: Rajita Sinha; Helen Fox; Kwang-Ik Hong; Mehmet Sofuoglu; Peter T Morgan; Ken T Bergquist Journal: Exp Clin Psychopharmacol Date: 2007-10 Impact factor: 3.157
Authors: Erin B Larson; Justin J Anker; Luke A Gliddon; Kyah S Fons; Marilyn E Carroll Journal: Exp Clin Psychopharmacol Date: 2007-10 Impact factor: 3.157
Authors: Angela E Waldrop; Sudie E Back; Kathleen T Brady; Himanshu P Upadhyaya; Aimee L McRae; Michael E Saladin Journal: Addict Behav Date: 2007-07-19 Impact factor: 3.913
Authors: Verica Milivojevic; Rajita Sinha; Peter T Morgan; Mehmet Sofuoglu; Helen C Fox Journal: Hum Psychopharmacol Date: 2014-11-03 Impact factor: 1.672
Authors: Sridevi Krishnan; Karan Agrawal; Rebecca R Tryon; Lucas C Welch; William F Horn; John W Newman; Nancy L Keim Journal: Physiol Behav Date: 2018-07-18